---
document_datetime: 2023-09-21 19:34:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_en.pdf
document_name: topotecan-actavis-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7035014
conversion_datetime: 2025-12-27 23:45:26.395933
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU number       | Name              | Strength   |
|-----------------|-------------------|------------|
| EU/1/09/536/001 | Topotecan Actavis | 1 mg       |
| EU/1/09/536/002 | Topotecan Actavis | 4 mg       |
| EU/1/09/536/003 | Topotecan Actavis | 1 mg       |
| EU/1/09/536/004 | Topotecan Actavis | 4 mg       |

Route of administration

Intravenous use

Intravenous use

Intravenous use

Intravenous use

Packaging vial (glass)

vial (glass)

vial (glass)

vial (glass)

Package size

1 vial

1 vial

5 vials

5 vials

Pharmaceutical form Powder for concentrate for solution for infusion Powder for concentrate for solution for infusion Powder for concentrate for solution for infusion Powder for concentrate for solution for infusion MedicinalIproductInoIlongerIauthorised